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Hemophilia A (HA) is the most frequent inheritable defect of the coagulation proteins.
The current standard of care for patients with HA is prophylactic factor infusion, which
is comprised of regular (2–3 times per week) intravenous infusions of recombinant or
plasma-derived FVIII to maintain hemostasis. While this treatment has greatly increased
the quality of life and lengthened the life expectancy for many HA patients, its high
cost, the need for lifelong infusions, and the fact that it is unavailable to roughly 75%
of the world’s HA patients make this type of treatment far from ideal. In addition, this
lifesaving therapy suffers from a high risk of treatment failure due to immune response
to the infused FVIII. There is thus a need for novel treatments, such as those using stem
cells and/or gene therapy, which have the potential to mediate long-term correction or
permanent cure following a single intervention. In the present review, we discuss the
clinical feasibility and unique advantages that an in utero approach to treating HA could
offer, placing special emphasis on a new sheep model of HA we have developed and on
the use of mesenchymal stromal cells (MSC) as cellular vehicles for delivering the FVIII
gene.
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HEMOPHILIA A AND THE NEED FOR BETTER TREATMENTS
Hemophilia A (HA) is the most commonly occurring inherita-
ble deficiency of coagulation (Mannucci and Tuddenham, 2001).
While the clinical severity of HA (based on FVIII plasma levels)
can vary, up to 70% of patients withHA present with a severe, life-
threatening phenotype, due to having less than 1% of the normal
plasma levels of FVIII activity (Kay and High, 1999; High, 2003;
Agaliotis et al., 2006). These patients suffer frequent spontaneous
hemorrhaging, which leads to hematomas, chronic painful and
debilitating arthropathies, and potentially life-threatening inter-
nal bleeding (Agaliotis et al., 2006). The current standard of care
for HA is prophylactic factor infusion, which is comprised of
regular (2–3 times per week) intravenous infusions of recombi-
nant or plasma-derived FVIII to maintain hemostasis. While the
availability of this protein-based treatment has greatly improved
the quality of life and extended the life expectancy for many
patients with HA, it is far from and ideal therapy. Patients are
sentenced to a lifetime of multiple intravenous infusions each
week, and are financially strapped with treatment costs that can
exceed $300,000/year. Even among the ∼25% of HA patients
worldwide who are fortunate enough to have access to FVIII pro-
phylaxis, approximately 30% will mount an immune response
to the infused FVIII, forming inhibitory antibodies (inhibitors)
to FVIII (Kaveri et al., 2007). In the best case scenario, these
inhibitors simply reduce the effectiveness of subsequent infusions
of FVIII; in the worst case scenario, they can lead to treatment fail-
ure, precluding restoration of hemostasis and putting the patient
at risk of a life-threatening bleed. These significant shortcomings
highlight the urgent unmet need for novel therapies that could
promise longer-lasting correction, or permanent cure, of HA.
In contrast to current protein-based therapeutics, a single gene
therapy treatment could promise lifelong improvement or per-
manent cure of HA; indeed, several aspects of HA make it an
ideal target disease for correction by gene therapy (Lipshutz et al.,
1999; Arruda, 2006; Ponder, 2006; Doering et al., 2007, 2009; Ide
et al., 2007; Shi et al., 2008; Nichols et al., 2009; Tellez et al.,
2010; High, 2011). First, FVIII, unlike the proteins that are miss-
ing/defective in many other genetic diseases, does not need to
be expressed in either a specific tissue or cell type to produce
a therapeutic effect. Although the majority of FVIII produced
within the body is thought to be synthesized within the liver
(Fahs et al., 2014), as long as FVIII is produced by cells that are
close enough to the vasculature to secrete the synthesized FVIII
into the circulation, FVIII can exert its appropriate clotting activ-
ity. Second, even if FVIII levels could be restored to only 3–5%
of normal, this seemingly minimal change would be predicted
to exert a marked clinical improvement and greatly improve the
quality of life of patients with severe HA, since it would con-
vert these patients to a moderate/mild phenotype. Conversely,
even FVIII levels as high as 150% of normal should be safe.
As such, FVIII has a very wide therapeutic window (Kay and
High, 1999). Armed with this knowledge, the hemophilias were
among the most promising, “Target 10,” group of diseases in
the roadmap the American Society of Gene and Cell Therapy
(www.ASGCT.org) recently provided to NIH director, Dr. Francis
Collins.
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SHEEP AS A PRECLINICAL MODEL OF HEMOPHILIA A
A number of animal models have been developed to evaluate new
methods of treating coagulation disorders, and also for preventing
and devising way to overcome inhibitor formation. Fortunately,
colonies of HA dogs in which spontaneous mutations occurred
within the FVIII gene (Hough et al., 2002; Lozier et al., 2002)
and FVIII-deficient mice produced via gene targeting/knockout
(Bi et al., 1995) are both available to study the biology of FVIII
and to begin developing/exploring gene-based strategies for treat-
ing HA. Pronounced therapeutic benefit has been demonstrated
in multiple studies in the murine models (Gallo-Penn et al., 1999;
Garcia-Martin et al., 2002; Reddy et al., 2002; Moayeri et al., 2004,
2005; Sarkar et al., 2004; Doering et al., 2007; Ide et al., 2007,
2010). Phenotypic correction has also been achieved in dogs with
HA, but correction in this more clinically predictive model has
proven to be much more difficult than in mice (Gallo-Penn et al.,
2001; Scallan et al., 2003). However, despite the promising results
that have been obtained in both these models, no clinical bene-
fit has yet been seen in any of the clinical gene therapy trials that
have been conducted to-date in human patients with HA. This is
in striking contrast to the recent successes that have been reported
in clinical gene therapy trials treating patients with hemophilia B
(HB) (Nathwani et al., 2011); the reasons for the marked differ-
ence in the ability of gene therapy to correct HA vs. HB are not, at
present, clear. Nevertheless, as a result of the disappointing out-
comes thus far, no active clinical trials are currently ongoing in
which gene therapy is being used to treat HA. This is especially
vexing when one considers that roughly 80% of all hemophilia
cases are HA.
The difficulties seen thus far translating success in animal
models into therapeutic benefit in human patients highlight
the importance of preclinical animal models that both precisely
mimic the disease process of HA, and closely parallel normal
human immunology and physiology. To this end, we used a
variety of reproductive technologies to successfully re-establish
a line of sheep (Bormann et al., 2006, 2007; Almeida-Porada
et al., 2007; Sanada et al., 2008; Porada et al., 2010), origi-
nally described by investigators at the Swiss Federal Institute of
Technology (Neuenschwander et al., 1992; Backfisch et al., 1994;
Neuenschwander and Pliska, 1994), that possess a spontaneous
mutation causing severe HA, which, if not treated immedi-
ately at birth, is fatal within the first hours/days of life. Upon
re-establishing this line, we fully characterized the clinical param-
eters of this new model (Bormann et al., 2006, 2007; Almeida-
Porada et al., 2007; Sanada et al., 2008; Porada et al., 2010). All
10 affected animals born thus far have presented with prolonged
umbilical cord bleeding, protracted nail (hoof) cuticle bleeding
time, bleeding following routine tail docking, and they have all
experienced multiple spontaneous episodes of severe bleeding,
including muscle hematomas, hematuria, and hemarthroses, all
of which have promptly responded to infusion of human FVIII.
Since aPTT can be fairly inaccurate when FVIII levels are very low,
we had our collaborators at the BloodCenter of Wisconsin and
at Emory University independently run a highly sensitive chro-
mogenic assay to accurately quantitate the level of FVIII activity
present in the circulation of these animals. The results of these
assays quickly explained the severe, life-threatening phenotype we
observed in this line of sheep, as FVIII activity was undetectable.
Just like human patients with severe HA, these sheep experience
frequent spontaneous bleeds into their “knees,” which, over time,
produce crippling arthropathies that ultimately lead to decreased
movement, difficulties walking, and eventually symptoms of pain
even just to stand up. These recurring spontaneous joint bleeds
make this line of sheep unique among animal models of HA. Also
in similarity to human patients, some of these sheep developed
inhibitors following administration of FVIII. However, since we
were restricted to treatment with human FVIII (we had not yet
cloned and sequenced ovine FVIII), it is not yet clear whether
these animals will also make inhibitors to the ovine protein. An
ongoing collaboration with investigators at Emory University has
recently resulted in the successful cloning and large scale pro-
duction of recombinant B domain-deleted ovine FVIII (Zakas
et al., 2012), making it possible to address this important ques-
tion and to construct gene therapy vectors encoding the native
ovine sequence for testing in this valuable model.
In addition to studying the clinical picture of these animals, we
also sequenced the entire coding region of the ovine FVIII gene to
define the precise molecular basis for their disease. This knowl-
edge of the nature of the disease-causing mutation enabled us to
then design a PCR-based RFLP that allows us to unequivocally
identify affected animals at birth and even in utero, using amniotic
fluid-derived cells (Bormann et al., 2006, 2007; Almeida-Porada
et al., 2007; Sanada et al., 2008; Porada et al., 2010). These stud-
ies revealed that HA in this line of sheep is caused by a frame
shift mutation that introduces a premature stop codon part way
through the FVIII coding region. Importantly, this type of muta-
tion has also been reported in many human HA patients (Park
et al., 2004). Since this line of sheep is, to our knowledge, the
only animal model of HA yet described that possesses this type of
mutation, these sheep provide a unique system in which to study
therapies in this context.
While another large animal model of HA would already be
of value, and the nature of the mutation present in these sheep
makes them unique as an HA model, sheep possess many char-
acteristics that make them an ideal preclinical model for gene
therapy, especially in the context of HA. Firstly, sheep share many
important physiological and developmental characteristics with
humans. As a result, they have been used extensively in the study
of mammalian fetal physiology, and the results obtained with
this model have been directly applicable to the understanding of
human fetal growth and development (Jeanblanc et al., 2014).
In contrast to dogs, pigs, and many other large animals which
tend to have large litters of offspring, sheep, like humans, typi-
cally give birth to only one or two offspring in each pregnancy.
Secondly, sheep are similar in size/weight to humans, both at
birth and as adults, making it possible to develop and test clin-
ically relevant doses of vector/cells directly in this model prior to
translating to the clinical arena. Thirdly, the development of the
immune system during fetal ontogeny has been thoroughly delin-
eated in sheep (Silverstein et al., 1966; Sawyer et al., 1978; Osburn,
1981; Tuboly et al., 1984; Maddox et al., 1987a,b,c), making this
model ideal for investigating the immune facets of treating HA
via gene therapy. An additional unique advantage to using sheep
to study HA treatment is that in sheep, like human, the majority
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of the FVIII carrier protein, vWF, is stored/located within their
platelets. This is in contrast to dog, in which vWF circulates free
in plasma (McCarroll et al., 1988; Parker et al., 1991). This key dif-
ference makes the sheep the most clinically relevant large animal
model in which to test the efficacy of platelet-targeted gene ther-
apy approaches for treating HA (Shi et al., 2006, 2008; Shi and
Montgomery, 2010; Montgomery and Shi, 2012). For these col-
lective reasons, we feel that sheep are an especially fitting model
in which to develop and test gene therapy treatments for HA.
FEASIBILITY AND JUSTIFICATION FOR TREATING HA PRIOR
TO BIRTH
Even if FVIII costs were reduced to the point that most HA
patients could afford prophylaxis, these patients would still
require recurrent, intravenous infusions throughout their lives,
and still have a significant risk of treatment failure due to inhibitor
induction. These problems, as well as many of the obstacles that
have precluded gene therapy from curing patients with HA (and
many other diseases) to-date, could likely be overcome/eliminated
by performing gene therapy prior to birth. At the present time,
HA can be diagnosed relatively early in gestation (10–12 weeks),
just like many other genetic diseases. The ability to diagnose HA
early in development makes it feasible to begin devising meth-
ods to try to correct this disease prior to birth. Fetal transfusions
and in utero stem cell-based therapies have safely been performed
clinically for decades (Flake and Zanjani, 1999; Troeger et al.,
2006). Indeed, to date, 46 in utero transplants have been per-
formed in human patients (Tiblad and Westgren, 2008; Tarantal
and Lee, 2010), for 14 different genetic disorders, including 1
case of HA (Troeger et al., 2006; Touraine, 2013). These stud-
ies have collectively provided unassailable proof that the early
human fetus can be accessedmultiple times with an extremely low
procedure-related risk, assuming that a minimally invasive, ultra-
sound guided approach is employed (Flake et al., 1996; Flake and
Zanjani, 1999; Tarantal et al., 2006; Troeger et al., 2006; Merianos
et al., 2008; Roybal et al., 2010; Tarantal and Lee, 2010). It is
important to note that it was studies performed in the fetal sheep
model that provided the experience and knowledge that led to the
first curative in utero transplant in a human patient (Flake et al.,
1996), emphasizing the value and importance of the fetal sheep
model for developing clinically viable approaches to therapy, and
for predicting clinical outcome. Using these established, clinically
proven methods to deliver a corrective FVIII gene early in ges-
tation could cure HA in utero, enabling the birth of a normal
healthy baby requiring no further treatments. Such a treatment,
if successful, would clearly represent a major advance, both from
an economic standpoint (one treatment rather than a lifetime of
expensive treatments several times each week), and with respect
to the quality of life of the patient.
Whilemost individuals with a family history of HA are encour-
aged to have prenatal screening (∼70–75% of new HA cases arise
in families with a history of HA), parents presented with a pre-
natal diagnosis of HA currently have only 2 possible choices:
pregnancy termination or the birth of a child with HA. The avail-
ability of a safe and effective in utero treatment would provide
parents a much-needed 3rd option, which would certainly pro-
vide the needed impetus for much more widespread prenatal HA
screening. In contrast to in vitro embryo screening and selection,
which has been proposed as a possible solution in families with
a history of HA and other genetic diseases, in utero gene therapy
requires only minimal equipment that would already be in place
for prenatal diagnosis, and should not be prohibitively expen-
sive. Several recent studies have provided conclusive evidence that
prenatal screening for the hemophilias can be cost-effective, even
when considering developing third world countries (Klein et al.,
2001; Sasanakul et al., 2003; Peyvandi, 2005). Moreover, another
recent study has shown it is now possible to diagnose HA in utero
by performing digital PCR on the small number of fetal cells
present within the mother’s peripheral blood, making it possible
to diagnose HA prenatally with essentially zero risk to the fetus or
mother (Tsui et al., 2011).
Although the clinical and financial advantages of in utero gene
therapy are compelling, in and of themselves, it is important to
realize that there are also features of the fetus that make it a better
gene therapy recipient than the adult (Matzinger, 2002; Porada
et al., 2004a,b). For instance, cell populations that are quiescent
in the adult, and largely refractory to transduction with many
commonly employed viral vectors, are actively cycling in the fetus
and amenable to transduction at relatively high efficiencies. For
example, we showed that a single intraperitoneal injection of a
small volume of γ-retroviral vector resulted in gene transfer lev-
els within the hematopoietic system of 5–6% (Porada et al., 1998,
2001a, 2002a; Tran et al., 2000); levels that would undoubtedly
be beneficial in HA. Further studies involving antibody selection
of CD34+ cells and serial transplantation/repopulation (Porada
et al., 1998, 2008; Tran et al., 2000), provided compelling evidence
that this approach successfully modified bona fide hematopoietic
stem cells, indicating this method could provide lifelong disease
correction.
Our results also demonstrated that this approach success-
fully transduced hepatocytes and hepatic endothelium at levels
that could well be therapeutic in HA, and defined the tempo-
ral window during gestation for optimal transduction of these
cells within the liver (Porada et al., 2005a). Concurrently, fetal
gene delivery experiments conducted in sheep, rodent, and non-
human primate models, by other investigators who employed a
variety of viral-based vectors, produced similar results (Porada
et al., 1998, 2002b, 2004a, 2005a,b; Lipshutz et al., 1999, 2000;
Schneider et al., 1999, 2002; Themis et al., 1999; Tarantal et al.,
2001a,b,c, 2005, 2006; David et al., 2003; Waddington et al., 2003,
2004; Chen et al., 2004a; Jimenez et al., 2005; Lee et al., 2005;
Park et al., 2009; Tarantal and Lee, 2010). The collective results of
these studies clearly support the ability of this method to deliver
a FVIII transgene to the nascent liver with sufficient efficiency to
convert severe HA patients to a moderate or, perhaps, even mild
phenotype (Porada et al., 2005a).
While the active cell cycling in the fetus enables efficient trans-
duction with vectors that require mitosis, it is important to note
that this ongoing proliferation in all of the fetal organs is also of
benefit when using vectors that do not have an absolute require-
ment for mitosis. Gene delivery early in gestation, regardless of
the vector employed, also makes it possible to achieve subsequent
expansion of these gene-corrected cells throughout the rest of ges-
tation. As such, even if the initial gene transfer only transduces a
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small number of the desired target cells, this subsequent expan-
sion could produce clinically useful levels of gene-correction by
birth.
As mentioned earlier, one of the biggest obstacles/drawbacks
to treating severe HA by repeated infusion of purified or recom-
binant FVIII protein is the formation of inhibitory antibodies
in ∼30% of patients. It is important to note that there are also
distinct immunologic benefits to performing gene therapy in
the developing fetus. Early in immunologic development, before
thymic processing of mature lymphocytes, the fetus appears to be
highly receptive to foreign antigens. Indeed, exposure to foreign
antigens during this period often results in sustained tolerance,
which can become permanent if the presence of the antigen is
maintained (Billingham et al., 1954). We have spent the last two
decades performing in utero gene transfer studies in the sheep
model (Porada et al., 1998, 2001a,b, 2004a, 2005a; Tran et al.,
2000; Park et al., 2003a,b, 2004), and have shown that it is possible
to take advantage of this unique temporal window of immuno-
naïveté to deliver exogenous genes during this period of gestation
and induce durable tolerance to the vector-encoded gene product
(Tran et al., 2001). This tolerance induction appears to involve
both cellular and humoral mechanisms, since antibody and cel-
lular responses to the transgene product were both significantly
diminished in these animals, even several years after fetal gene
transfer. Indeed, further mechanistic studies demonstrated that
gene delivery early in fetal development exploits several central
and peripheral tolerogenic avenues that exist in the fetus (Colletti
et al., 2008). These results strongly imply that fetal gene therapy,
even if it does not cure HA, would still be an ideal treatment
modality for this disease, since permanent immune tolerance to
FVIII could be induced. This would thus ensure that postnatal
therapy, be it protein- or gene-based, could proceed safely with-
out any of the immune-related problems that currently plagueHA
treatment.
To-date, the only experimental studies to directly investigate
fetal gene therapy for the treatment of the hemophilias have tar-
geted hemophilia B (factor IX deficiency) (Lipshutz et al., 1999;
Schneider et al., 1999, 2002; Themis et al., 1999; David et al.,
2003, 2011; Waddington et al., 2003, 2004; Chen et al., 2004a;
Mattar et al., 2011). This is most likely a result of the greater
ease with which FIX can be cloned into a variety of viral vectors,
and efficiently expressed upon transduction of appropriate target
cells; this is in marked contrast to the difficulties that were ini-
tially seen when attempting to express FVIII in the context of viral
vectors (Ponder, 2011). Because HA patients have at least a ten-
fold higher likelihood of developing inhibitors than hemophilia B
patients (Ehrenforth et al., 1992; Chitlur et al., 2009), these stud-
ies, while encouraging, leave unanswered the critical question of
whether fetal gene delivery’s ability to induce immune tolerance
to marker gene products and FIX will hold true for the induction
of tolerance to FVIII, given FVIII’s higher inherent immunogenic-
ity.We are currently addressing is important question in the sheep
model.
All of the afore-referenced studies demonstrated that the direct
injection of viral vectors into the developing fetus can be an
effective way of delivering an exogenous gene and achieving long-
term expression in multiple tissues and confirmed the therapeutic
potential of an in utero approach to gene therapy. However, for
this direct vector injection method of fetal gene delivery to move
forward into the clinical arena, vectors that can target specific cell
types will likely need to be developed, to eliminate the risk of off-
target modification of undesirable non-target cells, like those of
the germline (Park et al., 2004, 2009; Lee et al., 2005). Since such
vectors are currently not available, we have been testing the abil-
ity of mesenchymal stromal cells (MSC) to serve as vehicles for
delivering genes to the developing fetus to safely correct HA and
other diseases prior to birth. In the next section of this chapter, we
will discuss our rationale for using these cells as therapeutics and
summarize results to-date following in utero delivery of MSC.
MESENCHYMAL STROMAL CELLS (MSC) AS HA
THERAPEUTICS
Decades after the pioneering studies of Friedenstein on the mar-
row microenvironment (Friedenstein et al., 1974; Friedenstein,
1991), results of studies from various labs around the world have
revealed that mesenchymal stromal cells (MSC) possess a very
broad differentiation potential, both in vitro and in vivo, and
exhibit properties that suggest that at least some of the cells con-
tained within this population may be stem cells (Caplan, 1991;
Liechty et al., 2000; Mackenzie and Flake, 2001; Fukuda, 2002;
Jiang et al., 2002; Airey et al., 2004; Chen et al., 2004b; Kassem,
2004; Porada et al., 2006; Banas et al., 2007; Chamberlain et al.,
2007; Colletti et al., 2009a; Porada and Almeida-Porada, 2010).
MSC are very rare, only comprising roughly 0.001–0.01% of cells
within the marrow (Galotto et al., 1999). However, they can
be passaged extensively in vitro without a loss of differentiative
potential, making it possible to readily generate clinically rele-
vant numbers of these cells (Crop et al., 2009). Since MSC were
first discovered within the bone marrow, many of the studies
performed thus far have utilized MSC isolated from this tissue.
However, we and others have now shown that cells with the phe-
notype and functionality of MSC can also readily be isolated
from a variety of different tissues, including umbilical cord blood,
kidney, liver, lung, brain, fetal blood, and even adipose tissue col-
lected via liposuction (Zuk et al., 2001, 2002; Almeida-Porada
et al., 2002;Morizono et al., 2003; in "t Anker et al., 2003; Lee et al.,
2004a; Fan et al., 2005; Gotherstrom et al., 2005). Importantly
from the standpoint of in utero therapies, MSC have also been iso-
lated from the amniotic fluid and the chorionic villi, raising the
exciting possibility that autologous MSC could be used as cellular
therapeutics or gene delivery vehicles for in utero therapy (Poloni
et al., 2011; Shaw et al., 2011a,b; Fernandes et al., 2012; Karlsson
et al., 2012; Weber et al., 2012).
As discussed earlier, the liver is thought to be the body’s main
source of FVIII. Studies from our group and others over the past
decade have provided compelling evidence that MSC from vari-
ous sources can give rise, in vitro and in vivo, to cells which appear
identical to native hepatocytes, and have shown that transplanting
MSC in a range of model systems results in the generation of sub-
stantial numbers of hepatocytes, with resultant repair/correction
in a variety of inborn genetic defects and injuries (Almeida-
Porada et al., 2001a, 2003a, 2004; Schwartz et al., 2002; Theise
and Krause, 2002; Almeida-Porada and Zanjani, 2004; Fang et al.,
2004; Sakaida et al., 2004; Lee et al., 2004b; Luk et al., 2005; Sato
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et al., 2005; Zhao et al., 2005; Ishikawa et al., 2006; Oyagi et al.,
2006; Popp et al., 2006; Talens-Visconti et al., 2006; Aurich et al.,
2007, 2008; Banas et al., 2007, 2008, 2009; Chamberlain et al.,
2007; Colletti et al., 2007, 2009b; Higashiyama et al., 2007;Muraca
et al., 2007; Sgodda et al., 2007; di Bonzo et al., 2008; Enns and
Millan, 2008; Lysy et al., 2008; Zheng and Liang, 2008). We have
shown, in the fetal sheep model, that, by performing the trans-
plant at a stage in early gestation when the fetal immune system
is still relatively immature, it is possible to achieve significant lev-
els of human cell engraftment. Moreover, because this approach
induces donor-specific tolerance, these xenogeneic human cells
persist for the whole life of the transplanted animals (Almeida-
Porada et al., 2001a, 2004; Almeida-Porada and Zanjani, 2004).
Of direct relevance to HA treatment, we have demonstrated that,
after transplantation into fetal sheep, human MSC engraft at lev-
els of up to 12% within the recipient liver (Almeida-Porada et al.,
2000, 2001b, 2003b, 2004; Almeida-Porada and Zanjani, 2004;
Chamberlain et al., 2004, 2007; Porada and Almeida-Porada,
2006, 2010), and contribute to both the parenchyma and the
perivascular zones, placing them in an ideal location to deliver
FVIII into the circulation. Since FVIII levels of only 3–5% of nor-
mal would convert a patient with severe HA to amoderate or mild
phenotype, it seems reasonable to conclude that these levels of
engraftment should be highly therapeutic. In other recent studies,
we have demonstrated that MSC from various tissues through-
out the body endogenously produce and secrete biologically active
FVIII (Soland et al., 2014). Collectively, these results support the
notion that MSC are uniquely and ideally suited for treating HA.
However, upon further analysis, we found that, although MSC
engrafted at significant levels within the natural sites of FVIII
synthesis, the levels of FVIII production were too low to effec-
tively treat HA. If, however, one were to use gene transfer to
engineer MSC to express FVIII, it is likely that the levels of
MSC engraftment we routinely achieve following transplanta-
tion in utero would be beneficial/therapeutic in HA, especially
if newer, expression-optimized FVIII variants were used in the
gene therapy vectors (Gangadharan et al., 2006; Doering et al.,
2009; Dooriss et al., 2009; Ide et al., 2010). Importantly, MSC can
be efficiently transduced with all of the major viral vector sys-
tems that are in clinical use, including adenovirus (Bosch et al.,
2006; Bosch and Stice, 2007; Roelants et al., 2008), murine retro-
viruses (Meyerrose et al., 2007; Sales et al., 2007; Piccoli et al.,
2008; Roelants et al., 2008; Gnecchi and Melo, 2009), lentiviruses
(Zhang et al., 2002, 2004; Meyerrose et al., 2008; Fan et al., 2009;
Wang et al., 2009; Xiang et al., 2009), and AAV (Kumar et al.,
2004; Stender et al., 2007). Furthermore, in contrast to stud-
ies with hematopoietic stem cells (Racine et al., 1995; Fox and
Chowdhury, 2004; Muraca and Burlina, 2005), human MSC are
stable in culture, do not form tumors in vivo (unlikemurineMSC,
Tasso et al., 2009), and there is no evidence that transduction
can cause human MSC to undergo transformation or progres-
sion to clonal dominance. Instead, recent studies have shown
that, even following intentional induction of genomic instabil-
ity, human MSC undergo terminal differentiation rather than
transformation (Altanerova et al., 2009), with very rare transfor-
mants only arising after very extended in vitro propagation, and
being easily identifiable (and removable) based on their altered
cell surface marker profile (Pan et al., 2014). As such, MSC appear
to represent very safe cellular vehicles for delivering a therapeutic
gene.
Looking specifically at using MSC to treat HA, multiple stud-
ies have already proven that MSC can be efficiently transduced
with murine retroviral and lentiviral vectors with gene cassettes
encoding FVIII from a variety of species and produce/release
high levels of functional FVIII protein. Importantly, when FVIII
was purified from the tissue culture medium of transduced
MSC, its specific activity, electrophoretic mobility, and prote-
olytic activation pattern were all identical to commercially pro-
duced FVIII (Doering, 2008). Given the widespread distribution
and engraftment of MSC following their transplantation, the
ability of MSC to give rise, in vivo, to cells of numerous tissue
types, and their ability to efficiently process and secrete signif-
icant quantities of biologically active FVIII, it is not surprising
that we and others feel that MSC represent ideal vehicles for
delivering a FVIII transgene throughout the body, and thereby
providing long-term/permanent correction of HA (Van Damme
et al., 2003; Doering, 2008; Pipe et al., 2008; Porada et al.,
2011).
In addition to their widespread engraftment and their ability
to serve as delivery vehicles for the FVIII gene, MSC have rather
unique immunological properties that may further increase their
utility for treating HA. MSC do not normally express MHC class
II or the co-stimulatory molecules CD80 and CD82. As a result,
they do not induce allogeneic lymphocytes to proliferate, nor do
they serve as very effective targets for cytotoxic T cells or NK cells.
Actually, a growing body of evidence exists to support the con-
clusion that MSC can be transplanted across allogeneic barriers
without eliciting a pronounced immune response (Bartholomew
et al., 2001; Devine et al., 2001). Thus, it is theoretically possible
that HA (and other diseases as well) could be treated using “off-
the-shelf” MSC from an unrelated donor, which would greatly
facilitate the use of these cells for therapy. It has long been pre-
sumed that the immune system is immature/absent in the fetus at
the time when in utero transplant is performed. However, recent
studies conducted in mice by Mackenzie and Flake have chal-
lenged this assumption by showing that the engraftment rate
of allogeneic hematopoietic cells can be negatively affected by
not only the developing fetal immune system, but also by that
of the mother (Peranteau et al., 2007; Nijagal et al., 2011). As
such, the success of in utero therapies may also benefit from the
hypoimmunogenic state of MSC.
In addition to their unique immune properties, MSC also pos-
sess another interesting characteristic that is potentially of great
clinical value; the ability to selectively migrate to sites within the
body where injury/inflammation exist. Upon arriving at these
sites, the MSC then repair the damaged/diseased tissue by: (1)
releasing trophic factors that dampen inflammation and stim-
ulate the local tissue’s endogenous repair mechanisms; and (2)
engrafting within the target tissue and reprogramming to produce
tissue-specific cells (Jiang et al., 2005, 2006a,b). This property
raises the exciting possibility that, following infusion, FVIII-
expressing MSC might have the ability to selectively traffic to
active bleeds/sites of injury, thus directing the therapy to regions
of the body that are in greatest need of help.
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PRECLINICAL SUCCESS WITH MSC-BASED TREATMENT
FOR HA
Despite the multiple advantages of early intervention, there are
already roughly 1.6 × 10∧4 individuals with HA, in the US alone,
who obviously could not benefit from the development of a ther-
apy that would be administered prior to birth. Furthermore, over
25% of the mutations that cause HA arise de novo; as such, it is
highly improbable that this group of patients would undergo pre-
natal screening for HA. We therefore began investigating, in two
pediatric HA lambs, whether some of the afore-mentioned prop-
erties that make MSC ideally suited for delivering FVIII could
still be realized if the MSC engineered to express FVIII are deliv-
ered early in childhood. During their first months of life, both
HA lambs in this study were given frequent human FVIII treat-
ments in an effort to control multiple hematomas and recurring
bleeds in the leg joints, that had given rise to chronic, progressive,
debilitating hemarthroses. As a result of these joint bleeds, the two
sheep developed extreme postural and gait defects, which made it
difficult for them to even stand upright, and precluded them from
walking. Given the severe, life-threatening phenotype of the HA
sheep, we chose to use cells from the “father” of the two HA lambs
(haploidentical), rather than attempting to collect marrow from
the two HA lambs to isolate autologous MSC.
Based on our prior in utero studies, we knew that MSC should
engraft throughout all of the major organs (Feldmann et al., 1992;
Almeida-Porada et al., 2004; Aurich et al., 2006; Russo et al.,
2006; Chamberlain et al., 2007; Colletti et al., 2009a) and durably
express the vector-encoded genes (Feldmann et al., 1992; Zanjani
et al., 1993; Colletti et al., 2009a) following intraperitoneal (IP)
injection. The IP route also enabled the MSC to gradually enter
the circulation over an extended period of time, as they were
absorbed through the peritoneal lymphatics, rather than as a sin-
gle large bolus, as would occur via IV injection. The IP route
also allowed us to avoid the extensive lung-trapping which occurs
following IV administration of MSC, promising more efficient
delivery of the MSC to the desired target tissues, and eliminating
the clinical risk of emboli formation (Traas et al., 2007; Mancuso
et al., 2009).
MSC were simultaneously transduced with 2 lentiviral-based
vectors; one of which contained a cassette coding for an
expression/secretion optimized porcine FVIII (pFVIII) transgene
(Yamagami et al., 2006), and the second of which encoded eGFP,
to enable us to follow/trace the donor cells in vivo following injec-
tion. Two factors drove our choice to use a pFVIII transgene: (1)
the cDNA for ovine FVIII had not yet been cloned; and (2) prior
studies had shown that, even when expressed in human cells,
the pFVIII transgene was produced/secreted at levels that were
10–100 times higher than those seen with hFVIII (Gangadharan
et al., 2006; Doering et al., 2007, 2009). As such, we anticipated
that even if the transplanted MSC only engrafted/persisted at
relatively low levels, they should still be able to exert a clinical ben-
efit. Once the transduced MSC had been sufficiently expanded,
transduced MSC were transplanted into the peritoneal cavity of
the first animal under ultrasound guidance, without any prior
preconditioning of the recipient.
At various time points after transplantation, a highly sensitive
chromogenic assay was unable to detect any FVIII activity in the
circulation of this animal, but his clinical picture was markedly
improved within only days of the transplant. The animal stopped
experiencing spontaneous bleeds, and he enjoyed an event-free
clinical course, no longer requiring hFVIII infusions. What was
most remarkable, however, was that the animal’s joints recovered
fully. His existing hemarthroses resolved, restoring normal pos-
ture and gait, and allowing him to resume a normal activity level.
This is the first report describing phenotypic correction of severe
HA in a large animal model after transplanting cells modified
to express FVIII. It is also the first time that chronic debilitat-
ing hemarthroses have been reversed as a result of any type of
therapeutic intervention.
Encouraged by this first animal’s marked improvement, we
performed an identical transplant procedure on a second ani-
mal, using a four-fold higher cell dose, in the hopes of achieving
detectable FVIII activity in the circulation. Just as had occurred in
the first animal, this straightforward procedure resolved existing
hemarthroses in this second animal, and he promptly regained
normal activity. The transplant also enabled this second animal to
achieve factor-independence. These results thus confirm the abil-
ity of MSC to serve as highly effective cellular vehicles for delivery
a FVIII transgene, and establish their ability to exert a pronounced
clinical benefit in this large animal HA model. Nonetheless, the
plasma of this second animal, just like that of the first animal,
was completely devoid of FVIII activity. As such, the question of
the mechanism(s) whereby this procedure produced such clear
therapeutic benefit remains unanswered.
Following euthanasia, PCR analysis of tissues collected from
these animals confirmed widespread engraftment of signifi-
cant levels of MSC in all of the tissues we analyzed, including
liver, lymph nodes, intestine, lung, kidney, omentum, and thy-
mus. Subsequent analysis of frozen tissue sections by confocal
microscopy revealed large numbers of MSC had engrafted within
the synovia of the joints that were experiencing hemarthro-
sis at the time of transplant. Moreover, these MSC were still
expressing the vector-encoded FVIII transgene. These analyses
thus confirmed the intrinsic ability of transplanted MSC to
home to and persist within sites of ongoing injury/inflammation.
Furthermore, the continued production/release of FVIII by the
engrafted cells, locally within the joint, provided a mechanis-
tic explanation for the pronounced improvement this procedure
exerted on the animals’ joints. However, the long-term presence
of FVIII-expressing MSC within the animals’ joints cannot really
account for the clear systemic benefits we observed in these ani-
mals, the most striking of which was their complete cessation of
spontaneous bleeding events.
Confocal microscopy also demonstrated that transplanted
MSC had engrafted within the small intestine, in agreement
with what we had seen in our prior in utero studies (Feldmann
et al., 1992). Since proteins secreted from cells within the intes-
tine should have fairly easy access to the circulation, future
studies designed to enhance the levels of intestinal engraftment
could likely produce a dramatic improvement in the amount of
FVIII that is released into the systemic circulation. Aside from
the intestine and injured/diseased joints, MSC engraftment also
occurred in the liver, the lungs, and the thymus of the treated ani-
mals. Collectively, the results of the PCR and confocal analyses
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strongly support the conclusion that widespread durable engraft-
ment of MSC can be achieved in a large animal model following
transplantation in a postnatal setting, without the need for pre-
conditioning/ablation. However, the levels of engraftment seen
in these pediatric animals were substantially lower than those
obtained in our prior in utero studies. Moreover, despite the
marked clinical improvement and the widespread engraftment of
the transplanted MSC, both animals mounted a strong immune
response to pFVIII, which agrees with prior studies conducted
in HA mice (Gangadharan et al., 2006). These inhibitors exhib-
ited cross-reactivity to hFVIII, which was unanticipated, since
a good deal of clinical data exist to support the continued effi-
cacy of pFVIII products in human patients that have developed
anti-hFVIII inhibitors (VandenDriessche et al., 1999; Brown and
Lillicrap, 2002; Bhakta et al., 2006; Son et al., 2006).
Therefore, while this postnatal approach proved that MSC
can serve as cellular vehicles to deliver a FVIII transgene and
produce a therapeutic benefit, we feel it is safe to conclude
that administering this same treatment in utero would have a
more pronounced and more durable effect, since higher levels of
donorMSC engraftment could be achieved, and because inhibitor
formation could be avoided due to the induction of immune
tolerance to the FVIII transgene.
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